Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Market Closed - Nasdaq
Other stock markets
 21:30:00 15/05/2024 BST 		5-day change 1st Jan Change
4.92 USD +1.44% Intraday chart for Moleculin Biotech, Inc. +4.68% -61.79%
05-13 Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024
05-10 Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
PR
Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
PR
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
PR
Transcript : Moleculin Biotech, Inc. - Special Call
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
PR
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
CI
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
AQ
Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman
CI
Transcript : Moleculin Biotech, Inc. - Special Call
European Medicines Agency Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia
AQ
Sector Update: Health Care Stocks Ease in Afternoon Trading
MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU
MT
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
PR
Top Premarket Decliners
MT
Transcript : Moleculin Biotech, Inc. - Special Call
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
PR
Moleculin to Participate in the Virtual Investor Lunch Break, the Moleculin Opportunity
AQ
Sector Update: Health Care Stocks Advance Late Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. News Moleculin Biotech, Inc.